Oppenheimer Asset Management Inc. Has $13.11 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Oppenheimer Asset Management Inc. decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 13.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 39,461 shares of the company’s stock after selling 6,012 shares during the period. Oppenheimer Asset Management Inc. owned 0.13% of Medpace worth $13,110,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Iron Triangle Partners LP bought a new stake in shares of Medpace in the 3rd quarter valued at $64,371,000. Wellington Management Group LLP grew its holdings in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock worth $138,612,000 after acquiring an additional 109,886 shares during the period. DF Dent & Co. Inc. grew its holdings in Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock worth $53,841,000 after acquiring an additional 105,659 shares during the period. Caisse DE Depot ET Placement DU Quebec bought a new position in shares of Medpace in the 3rd quarter worth about $23,321,000. Finally, Swedbank AB lifted its stake in shares of Medpace by 245.5% in the 4th quarter. Swedbank AB now owns 77,400 shares of the company’s stock valued at $25,715,000 after purchasing an additional 55,000 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Performance

Shares of Medpace stock opened at $326.11 on Friday. The stock has a market capitalization of $9.94 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The stock has a 50 day moving average price of $342.86 and a two-hundred day moving average price of $346.05.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.